Sector Gamma As buys $39.9 Million stake in Boston Scientific Corporation (BSX)

Boston Scientific Corporation (BSX) : Sector Gamma As scooped up 362,890 additional shares in Boston Scientific Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 27, 2016. The investment management firm now holds a total of 1,766,250 shares of Boston Scientific Corporation which is valued at $39.9 Million.Boston Scientific Corporation makes up approximately 7.48% of Sector Gamma As’s portfolio.

Other Hedge Funds, Including , Hemenway Trust Co sold out all of its stake in BSX during the most recent quarter. The investment firm sold 2,020 shares of BSX which is valued $45,612. Arrowstreet Capital Limited Partnership added BSX to its portfolio by purchasing 247,700 company shares during the most recent quarter which is valued at $5.5 Million. Boston Scientific Corporation makes up approx 0.02% of Arrowstreet Capital Limited Partnership’s portfolio.Blair William Coil reduced its stake in BSX by selling 2,283 shares or 5.54% in the most recent quarter. The Hedge Fund company now holds 38,896 shares of BSX which is valued at $870,104. Boston Scientific Corporation makes up approx 0.01% of Blair William Coil’s portfolio.Qs Investors reduced its stake in BSX by selling 2,714 shares or 12.43% in the most recent quarter. The Hedge Fund company now holds 19,124 shares of BSX which is valued at $427,804.

Boston Scientific Corporation closed down -0.12 points or -0.53% at $22.63 with 1,63,28,613 shares getting traded on Tuesday. Post opening the session at $22.74, the shares hit an intraday low of $22.54 and an intraday high of $22.76 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Boston Scientific Corporation reported $0.28 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $0.24. The company had revenue of $1964.00 million for the quarter, compared to analysts expectations of $1912.86 million. The company’s revenue was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.21 EPS.

Many Wall Street Analysts have commented on Boston Scientific Corporation. Company shares were Reiterated by RBC Capital Mkts on Apr 28, 2016 to “Outperform”, Firm has raised the Price Target to $ 25 from a previous price target of $22 .Company shares were Reiterated by Stifel on Apr 28, 2016 to “Buy”, Firm has raised the Price Target to $ 25 from a previous price target of $22 .Company shares were Reiterated by Wedbush on Apr 28, 2016 to “Neutral”, Firm has raised the Price Target to $ 23 from a previous price target of $19 .

Boston Scientific Corporation develops manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology which includes Drug-Eluting Coronary Stent Systems Intravascular Imaging devised and Coronary Technology products such as guide wires guide catheters and balloon catheters among others; Peripheral Interventions (PI) which include stents balloon catheters wires peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM) which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP) which include steerable RF ablation catheters intracardiac ultrasound catheters diagnostic catheters delivery sheaths and other accessories; Endoscopy which includes Spyglass System WallFlex Colonic Stents Resolution Clip and Expect Aspiration Needle among others; Urology and Women’s Health and Neuromodulation.

Leave a Reply

Boston Scientific Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Boston Scientific Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.